CN111616994A

CN111616994A - A composition comprising Chinese holly extract for preventing or treating inflammation and its application

Info

Publication number: CN111616994A
Application number: CN201910888012.5A
Authority: CN
Inventors: 尹锡均; 金旻智; 郑秀敬; 姜承贤; 朴明三
Original assignee: Cosmax Inc
Current assignee: Cosmax Inc
Priority date: 2019-02-28
Filing date: 2019-09-19
Publication date: 2020-09-04
Also published as: KR102236417B1; KR20200104996A

Abstract

The present invention relates to a composition for preventing or treating inflammation comprising a Chinese holly extract and a method for preventing, ameliorating or treating inflammation in a subject. According to an aspect of the present invention, the extract of Chinese holly has an excellent effect of improving skin inflammation or skin irritation, and thus can be applied to various fields such as cosmetics, foods, pharmaceutical compositions, and the like.

Description

A composition comprising Chinese holly extract for preventing or treating inflammation and its application

Cross Reference to Related Applications

This application claims priority and benefit from korean patent application No.10-2019-0023533, filed on 28.02/2019, which is incorporated herein by reference for all purposes as if fully set forth herein.

Technical Field

The present invention relates to a composition for preventing or treating inflammation comprising a Chinese holly extract and a method for preventing, ameliorating or treating inflammation in a subject.

Background

The inflammatory phenomenon causes a large increase in various types of polymorphonuclear leukocytes (PMNs) and immune substances, and these increased cells can be treated and defended by secreting proteases, cytokines, and the like, which are products of various inflammatory cells. However, this effect can cause harmful damage to adjacent tissue cells and non-cellular components. Thus, normal function is restored after passing through the initial state of inflammation under appropriate conditions, but if the stimulus stimulating inflammation is not eliminated or continues to be produced, chronic inflammation is eventually caused, thereby causing more serious tissue damage.

The morphologies of typical skin problems associated with inflammation include atopy and acne, with atopy being described below. The skin disease called "atopic dermatitis" or "atopic eczema" is a chronic and recurrent disease that commonly occurs in infants and children, and the vicious circle of worsening, remission, recurrence, etc., of symptoms such as severe pruritus (pruritus) and skin eczema, etc., due to various causes, continues. The direct cause of clinical symptoms of atopic dermatitis is allergy to the reduction of skin defense function and skin protection function of allergens or skin immune reaction. The first reason is that the dysfunction of keratinocytes, i.e., the structural defect of the stratum corneum of the skin, causes the reduction of the skin moisturizing function and skin barrier function, and bacteria and foreign substances, which are difficult to permeate in normal skin, invade the skin to easily induce irritation and allergic reactions. The second cause is allergy to skin immune reaction, and several immune abnormalities that appear when atopic dermatitis occurs include increased synthesis of immunoglobulin (IgE), increased expression of IgE receptor in B lymphocyte and monocyte by immunoglobulin, increased secretion of histamine by mast cell/basophil, increased delayed type anaphylaxis, increased secretion of eosinophil (eosinophil), increased secretion of interleukin IL-4, IL-5 and IL-13 by T lymphocyte type 2 (Th2lymphocyte), decreased secretion of interferon INF- γ by T lymphocyte type 1, and the like. In addition, a part of various inflammatory reaction cytokines caused by allergy of immune reaction causes dysfunction of keratinocytes, and its circulation process aggravates atopic dermatitis because dysfunction of skin barrier induces inflammatory reaction and the induced inflammatory reaction induces dysfunction of skin barrier again. On the other hand, anti-inflammatory action is a mechanism that defends against inflammation, a local physiological response that protects the body from factors that are or may be harmful to tissues. When these inflammatory phenomena are excessively induced, proteases, which are inflammatory cell products, destroy cells and connective tissues, and damage of the connective tissues reduces skin elasticity and promotes skin aging, so that healthy skin cannot be maintained.

On the other hand, Chinese holly (Ilex cornuta) is a dicotyledonous plant belonging to the family Aquifoliaceae (Aquifoliaceae), which is up to 4 to 5 meters. The leaves are in the shape of a thick oval hexagon with a thorn at the tip and the red fruit ripens from month 9 to month 10. Southern mountain peninsula, skimmia, and jizhou islands grown in korea. In Korean medicine, leaves and fruits are used for medicinal purposes. The leaves have the effects of dispelling wind, strengthening, etc., and the fruits have the effects of strengthening essence and promoting blood circulation ("wild weeds beneficial to the body", 11/15/2009, NEXUS co., Ltd.). However, the effect of Chinese holly on the anti-inflammation and sensitivity improvement of skin has not been reported.

Disclosure of Invention

An aspect of the present invention provides a composition for preventing, improving or treating skin inflammation or skin irritation, comprising an extract of Chinese holly (Ilex cornuta) as an effective ingredient.

Another aspect of the present invention provides a method for preventing, improving or treating skin inflammation or skin irritation in a subject, the method including the step of administering a holly extract to the subject in an amount effective to prevent, improve or treat skin inflammation or skin irritation.

Another aspect of the present invention provides a use of a composition comprising a holly extract for the preparation of a cosmetic for preventing or treating skin inflammation.

Another aspect of the present invention provides a use of a composition comprising a holly extract for the preparation of a medicament for preventing or treating skin inflammation.

An aspect of the present invention provides a composition for preventing or improving skin inflammation or skin irritation, comprising a ilex cornuta extract as an effective ingredient.

In one aspect of the present invention, the ilex cornuta extract has an excellent effect of inhibiting the expression of inflammatory cytokines, inflammatory chemokines and Thymic Stromal Lymphopoietin (TSLP) caused by irritation, skin irritation, and thus can be used for preventing, improving or relieving skin inflammation or skin irritation.

The terms "preventing, ameliorating, or treating skin inflammation" are used interchangeably with "anti-inflammation" and may refer to the action of relieving an immune response to inhibit NO production, inflammatory cytokines, inflammatory chemokines, or TSLP expression.

The composition has an excellent effect in preventing, ameliorating or treating atopic dermatitis, pruritus, redness, erythema, eczema, seborrheic dermatitis, psoriasis and acne by an anti-inflammatory effect.

The term "comprising as an active ingredient" means that the extract of chinese holly is added to the composition of the present invention in an amount having the effect of improving skin inflammation and relieving irritation, and also means that various ingredients are added as auxiliary ingredients and formulated (formulation) into various forms for drug delivery, stabilization, and the like.

The term "improvement" may refer to the alleviation of the condition or at least all actions that reduce a treatment-related parameter, such as the degree of symptoms.

The term "prevention" refers to any behavior close to that of a normal control group by inhibiting or delaying skin inflammation or skin irritation symptoms by administering a composition comprising the ilex cornuta extract.

The term "treatment" refers to any action of improving, or beneficially changing, the skin inflammation or skin irritation symptoms in the same or similar manner as in a normal control group by administering a composition comprising the ilex cornuta extract.

The ilex cornuta extract having the activity of preventing and improving skin inflammation or skin irritation can be extracted from various organs of natural, hybrid and variant plants, for example, not only from roots, stems, leaves, flowers, fruit bodies, pericarps, but also from plant tissue cultures, and most preferably from ilex cornuta leaves.

The term "ilex cornuta" is a dicotyledonous plant belonging to the family Aquifoliaceae (Aquifoliaceae), which is up to 4 to 5 meters. The leaves are in the shape of a thick oval hexagon with a thorn at the tip and the red fruit ripens from month 9 to month 10. Southern mountain peninsula, skimmia, and jizhou islands grown in korea. In Korean medicine, leaves and fruits are used for medicinal purposes. It is reported that the leaves have wind-dispelling, strengthening, etc. effects, and the fruits have a potent effect and contribute to blood circulation. According to an aspect of the present invention, the chinese holly may be chinese holly (Ilex x wandoensis) grown in skimmia.

The chinese holly extract may be a solvent extract extracted with an extraction solvent, a fraction obtained by adding a fraction solvent to an extract prepared by extraction with an extraction solvent, or a purified product obtained in the fraction by chromatography.

The extraction solvent may be water, an organic solvent or a mixture thereof which can be used for extracting natural substances. The extraction solvent may be water, a C1 to C6 alcohol, or a mixture thereof, such as water or ethanol.

The ilex cornuta extract can be prepared by a conventional method for producing a plant extract. More specifically, the ilex cornuta extract can be prepared by a method of adding an extraction solvent to a pulverized product obtained by pulverizing a dried ilex cornuta from which impurities have been removed, and extracting it. The extraction method using the solvent may be a cold-dipping extraction method, a hot-dipping extraction method, a reflux extraction method or an ultrasonic pulverization extraction method. The extract may be obtained by incubating the chinese holly in a solvent to extract an active ingredient from the solvent. The incubation can be performed at a temperature from 4 ℃ to reflux temperature, from 4 ℃ to 100 ℃, from 4 ℃ to 80 ℃, from 4 ℃ to 60 ℃, from 4 ℃ to 50 ℃, from 4 ℃ to 40 ℃, from 4 ℃ to 35 ℃, from 4 ℃ to 30 ℃, from 4 ℃ to 25 ℃, or at room temperature. The incubation may be carried out for a time sufficient to extract the active ingredient from the solvent. The time may be 1 hour to 2 weeks, 1 hour to 1 week, 1 hour to 5 days, 1 hour to 3 days, 12 hours to 5 days, 12 hours to 3 days, 12 hours to 2 days, 24 hours to 5 days, or 24 hours to 3 days.

The composition may be a composition that inhibits an inflammatory response by reducing expression of Thymic Stromal Lymphopoietin (TSLP), inflammatory cytokines, and inflammatory chemokines.

The composition may be a composition that alleviates skin irritation by reducing the expression of TSLP, inflammatory cytokines, and inflammatory chemokines that are increased by irritation.

A composition according to a particular embodiment may comprise an effective amount of the extract or comprise the extract as an active ingredient. The effective amount may be appropriately selected depending on the individual. The effective amount may be determined based on factors including the following, as well as other factors well known in the physiological to medical arts: disease to the severity of the disease condition, age, weight, health, sex of the individual, sensitivity of the individual to the extract, time of administration, route of administration and rate of excretion, period of administration, other compositions mixed or used simultaneously with the composition.

The composition for preventing, improving or treating skin irritation according to an embodiment may further include a cosmetically, dietetically or pharmaceutically acceptable excipient or carrier. The carrier may be an excipient, disintegrant, binder, lubricant, or combination thereof. The excipient may be microcrystalline cellulose, lactose, low substituted hydroxycellulose, or a combination thereof. The disintegrant may be sodium starch glycolate, anhydrous dibasic calcium phosphate, or a combination thereof. The binding agent may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The formulation type of the composition may be a non-oral administration dosage form. The non-oral administration dosage form may be an injection or a skin external preparation. The skin external preparation can be cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, medicated bandage, lotion or their combination.

The skin external preparation may be appropriately mixed with ingredients of skin external preparations generally used in cosmetics, pharmaceuticals, and the like, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, perfumes, colorants, various skin nutrients, and the like, as necessary.

The skin external preparation may be appropriately mixed with disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, metal chelating agent such as gluconic acid, caffeine, tannin, verapamil, licorice extract, glabridin, hot water extract of Cirsium japonicum fruit, various crude drugs, tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts, and saccharides such as vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.

The composition according to a particular embodiment may be a cosmetic composition. In this case, the extract may be prepared into a dosage form including: lotions (lotions), emollients, lotions, astringents (astringents), lotions, milk lotions (milk lotions), moisturizing lotions, nutritional liquids, massage creams, nutritional creams, moisturizing creams, hand creams, foundations, essences, nourishing essences, films, soaps, cleansing foams, cleansers, cleansing creams, body lotions, body cleansing liquids, suspensions, gels, powders, pastes (pastes), masks or sheet masks, or spray compositions.

In addition, it can be applied in various forms such as liquid phase, cream phase, stick phase and solid phase. Compositions of such dosage forms may be prepared according to methods conventional in the art. The cosmetic composition may further comprise preservatives, stabilizers, surfactants, solvents, moisturizers, emollients, ultraviolet absorbers, preservatives, bactericides, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, cold sensates or antiperspirants. The mixing amount of the additional ingredients such as the above-mentioned moisturizer and the like can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, and can be 0.001% to 5%, specifically, 0.01% to 5%, based on the total weight of the composition.

The composition according to a particular embodiment may be a food composition. In this case, the composition can be prepared in the form of conventional health food known in the art. The food composition may be prepared in the form of general formulations such as powder, granules, tablets, pills, capsules, suspensions, oils, syrups, infusions, liquids, extracts and the like, and in the form of any health foods such as meats, sausages, breads, chocolates, candies, snacks, cookies, pizzas, noodles, other noodles, chewing gums, jellies, dairy products including ice creams, various soups, beverages, teas, drinkables, alcoholic beverages, and vitamin complexes. In order to formulate the health food, a food-acceptable carrier or additive may be used, and any carrier or additive known in the art to be usable may be used to prepare a desired formulation. The additives may include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acids and salts thereof, alginic acids and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents for carbonated beverages, and the like. In addition, the additive may contain pulp for preparing natural fruit juice, fruit juice beverage and vegetable beverage.

These additive components may be used alone or in combination, and the proportion of the additive may be 0.001% to 5%, specifically, 0.01% to 5%, based on the total weight of the composition.

The content of the extract in the food composition may be appropriately determined depending on the purpose of use (prevention or improvement). Generally, 0.01 to 15 weight percent of the total weight of the food may be included, and when manufactured as a beverage, a ratio of 0.02 to 10g, specifically, a ratio of 0.3 to 1g may be contained, based on 100 mL.

The beverage may further include other ingredients than the extract, and may further include various flavors or natural carbohydrates, etc. generally used for beverages. The natural carbohydrate may contain conventional sugars such as monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), polysaccharides (e.g., dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, erythritol. In addition, the spice may contain natural spices (e.g., Thaumatin (Thaumatin), stevia extract, etc.) and synthetic spices (e.g., saccharin, aspartame, etc.). The proportion of the natural carbohydrate is generally about 1g to 20g, specifically about 5g to 12g, per 100mL of the beverage.

The composition according to a particular embodiment may be a pharmaceutical composition. In particular, the pharmaceutical composition may be a pharmaceutical composition for preventing or treating a skin disease. The skin disease may be an inflammatory skin disease or a disease caused by skin irritation.

The skin inflammatory disease may refer to all diseases caused by skin irritation and immune irritation. For example, the skin inflammatory diseases may include, but are not limited to, atopic dermatitis, pruritus, redness, erythema, eczema, seborrheic dermatitis, psoriasis, acne, and the like. The pharmaceutical composition according to an embodiment can prevent or treat inflammatory diseases of the skin by maintaining moisture of the skin, preventing moisture loss of the skin, enhancing skin barrier, and anti-inflammatory effects.

The impaired skin barrier function may refer to all changes that occur in the skin due to a decrease or impairment of the skin barrier function. For example, the skin barrier function impairment may include, but is not limited to, skin wrinkle increase, dryness, dermatitis, atopic dermatitis, allergic dermatitis, acne, and the like. The pharmaceutical composition according to an embodiment can prevent or treat impairment of skin barrier function by improving the recovery rate of transdermal water loss.

The skin aging may refer to all tangible and intangible changes that occur in the skin with age. For example, the skin aging may include, but is not limited to, increased skin wrinkles, dryness, decreased wound healing capacity, decreased skin immune function. The pharmaceutical composition according to an embodiment can prevent or treat skin aging by enhancing skin barrier, maintaining skin moisture, and preventing skin moisture loss.

In another aspect of the invention, a method for soothing the skin of an individual is provided comprising the step of applying the composition to the individual. The composition is the same as described above.

In particular, the method may be a method of ameliorating or treating inflammation, a method of ameliorating or treating skin irritation in a subject.

The terms "administered", "introduced" and "transplanted" are used interchangeably and may refer to a method of achieving at least partial localization of a composition according to an embodiment to a desired site or placement of a composition according to an embodiment into an individual according to a route. The extract or at least a portion of the extract component of the composition according to a particular embodiment may be administered by any suitable route for delivery to a desired location in a living body.

Administration can be performed by any method known in the art. Administration can be carried out directly to the individual in any way, by routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. The administration may be performed systemically or locally.

The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat or cat. The subject may be a subject in need of soothing the skin, for example in need of treatment of anti-inflammatory and atopic dermatitis.

The administering may be administering the ilex cornuta extract to the subject daily in the following amounts: 0.1mg to 1000mg, e.g., 0.1mg to 500mg, 0.1mg to 100mg, 0.1mg to 50mg, 0.1mg to 25mg, 1mg to 1000mg, 1mg to 500mg, 1mg to 100mg, 1mg to 50mg, 1mg to 25mg, 5mg to 1000mg, 5mg to 500mg, 5mg to 100mg, 5mg to 50mg, 5mg to 25mg, 10mg to 1000mg, 10mg to 500mg, 10mg to 100mg, 10mg to 50mg, or 10mg to 25 mg. However, the administration amount may be variously prescribed depending on factors such as formulation method, administration method, age, body weight, sex, pathological condition, diet, administration time, administration route, excretion rate, and response sensitivity of the patient, and the like, and those skilled in the art will understand that the administration amount may be appropriately adjusted in consideration of these factors. The number of administrations may be 1 time per day or 2 times or more within a range of clinically acceptable side effects, with respect to the administration site, administration may be at one or two or more, and the total number of administration days per day or every 2 to 5 days may be 1 to 30 days at the time of one treatment. If desired, the same treatment can be repeated after an appropriate time. For animals other than humans, the administration may be performed in the same amount as humans per kg of the administration amount, or in an amount converted to the administration amount by a volume ratio (for example, an average value) of organs (heart and the like) of the target animal and the human, or the like.

Drawings

The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate exemplary embodiments of the invention and together with the description serve to explain the inventive concept.

FIG. 1 is a graph showing the results of real-time PCR measurements of the change in expression of TSLPmRNA in human keratinocytes derived from ethanol extracts of leaves (a), stems (b) and roots (c) of Chinese holly (for control group # #: p < 0.01; for + control group # #: p < 0.01; p < 0.05).

FIG. 2 is a graph showing the results of real-time PCR measurements of the expression change of MDC mRNA in human keratinocytes based on ethanol extracts (10ppm) of leaves, stems and roots of Chinese holly (for-control group # #: p < 0.01; for + control group #: p < 0.01; p < 0.05).

FIG. 3 is a graph showing the results of real-time PCR measurement of the change in expression of TARCmRNA in human keratinocytes based on ethanol extracts (10ppm) of leaves, stems and roots of Holly cornuta (for control # #: p < 0.01; for + control # #: p < 0.01; p < 0.05).

FIG. 4 is a graph showing the results of ELISA measurement of the change in the expression of TARC protein in human keratinocytes based on ethanol extracts (10ppm) of leaves, stems and roots of Holly cornuta (for-control group # #: p < 0.01; for + control group #: p < 0.01).

FIG. 5 is a graph showing the results of real-time PCR measurement of the change in expression of IL-6mRNA in human keratinocytes based on ethanol extracts (10ppm) of leaves, stems and roots of Holly cornuta (for-control group # #: p < 0.01; for + control group #: p < 0.01).

FIG. 6 is a graph showing the results of real-time PCR measurement of the change in expression of IL-8mRNA in human keratinocytes based on ethanol extracts (10ppm) of leaves, stems and roots of Holly cornuta (for-control group # #: p < 0.01; for + control group #: p < 0.01).

Detailed Description

Hereinafter, the present invention will be described in more detail by examples. However, these examples are for the purpose of describing the present invention, and the scope of the present invention is not limited to these examples.

Example 1: preparation of Chinese Holly extract

In this example, Chinese holly (Ilex cornuta, Ilex x wandoensis) was purchased from the kyoto market (seoul, korea). Leaves, stems and roots of purchased Chinese holly were dried and pulverized, and 100ml of 70% (v/v) ethanol was added to each 10g of the powder, followed by standing at room temperature for 1 day. The filtrate (filtrate) obtained by filtering the solution with filter paper was concentrated under reduced pressure at 40 ℃ to 60 ℃ to obtain 3.7g of an extract (hereinafter referred to as "ethanol extract") therefrom.

Experimental example 1: evaluation of the inhibitory Properties of Thymic Stromal Lymphopoietin (TSLP)

1.1 culture of HaCaT cells as human skin keratinocyte cell lines

HaCaT as human keratinocytes was purchased from korean cell line bank and cultured in DMEM medium containing 10% Fetal Bovine Serum (FBS) and antibiotics. 75T flasks and 6-well plates were used as culture vessels, and the culture was performed in a 37 ℃ incubator supplied with 5% carbon dioxide. The medium was changed every 3 to 4 days, and when the cells proliferated excessively, subculture was performed. HaCaT at 5X10⁵Perwell, and after 24 hours of incubation, washed with Phosphate Buffered Saline (PBS). Washed HaCaT was washed with 10. mu.g/ml Poly I: c and 10ng/ml IL-4 were added to the DMEM medium containing no FBS per well, and ethanol extracts of chinese holly leaves, stems, and roots were diluted to final concentrations of 0.1ppm, 1ppm, and 10ppm, respectively, and then added to each well and cultured.

1.2 measurement of changes in expression of TSLP

TSLP is classified as a top-grade cytokine that initiates a type 2 helper T cell-mediated immune deviation believed to be responsible for atopic dermatitis. And Poly I: after culturing for 4 hours with C/IL-4, cDNA was synthesized in HaCaT cells, and the gene expression level of TSLP was measured using the synthesized cDNA as a template and real-time polymerase chain reaction (real-time PCR) using Sayborgylin (SYBR Green master mix) and primers. As a positive control group, dexamethasone (Dex) was treated with-concentration. The relative values of the internal control gene β -actin were corrected by the Ct (threshold cycle) method for comparison.

Primer sequences used in the examples of the present invention are shown in table 1 below.

[ TABLE 1 ]

(-): a negative control group; (+): poly I: c and IL-4 treatment groups; dex: dexamethasone-treated group as positive control group; 0.1: chinese holly extract.

As shown in fig. 1, with unused poly I: c and IL-4 treated HaCaT cells compared, with poly I: the expression of TSLP was considerably increased in C and IL-4 treated HaCaT cells (+). The expression concentration of TSLP mRNA was decreased dependently by the treatment of the ilex cornuta extract. In particular, it was confirmed that the expression of TSLP was reduced to a level similar to that of HaCaT cells treated with dexamethasone as a positive control group by the treatment of ilex cornuta extract at 1ppm or more.

Experimental example 2: evaluation of the inhibitory Properties of inflammatory chemokines

In order to evaluate the inflammatory chemokine inhibitory properties of ilex cornuta extract, the changes in the expression of macrophage-induced chemokine (MDC) and thymus and activation-regulated chemokine (TARC), which are inflammatory chemokines, were measured in the same manner as in experimental example 1.1. TARC is also known as chemokine (C-C motif) ligand 17(CCL 17).

As shown in fig. 2 and 3, it was confirmed that mRNA expression of MDC and TARC increased by the treatment of poly I: C and IL-4 was significantly reduced by the treatment of ethanol extract of leaves, stems, and roots of ilex cornuta.

(-): a negative control group; (+): poly I: c and IL-4 treatment groups; dex: dexamethasone-treated group as positive control group.

In addition, changes in chemokine expression were measured using an ELISA kit. Mixing HaCaT (5x 10)⁵/well) cells were cultured in FBSDMEM medium for 24 hours,then, the leaf, stem, and root extracts of ilex cornuta and poly I, C10. mu.g/ml and IL-410 ng/ml were simultaneously treated in DMEM without FB, and further cultured for 72 hours. Human CCL17/TARC ELISA kit (R) was then used&Company D) the supernatant of each well was quantified.

Experimental example 3: evaluation of inflammatory cytokine inhibitory Properties

In order to evaluate the inflammatory cytokine inhibitory properties of the Chinese holly extract, changes in the expression of IL-6 and IL-8 as inflammatory cytokines were measured in the same manner as in Experimental example 1.1.

As shown in FIGS. 5 and 6, it was confirmed that the mRNA expression of IL-6 and IL-8 increased by the treatment of poly I: C and IL-4 was considerably reduced by the treatment of ethanol extract of leaves, stems, and roots of Ilicis cornuta L. In particular, it was confirmed that the expression of IL-8mRNA was significantly reduced by the treatment of ethanol extract of Ilicis folium compared with other sites.

Therefore, since the ethanol extract of leaves, stems, and roots of holly exhibits excellent inflammation inhibitory and irritation-relieving effects by inhibiting the expression of TSLP, inflammatory chemokines, and inflammatory cytokines, it has efficacy of preventing, improving, or treating diseases caused by inflammation such as atopic dermatitis, pruritus, and the like.

Dosage form example 1: preparation of cream

A cream including the ilex cornuta extract was prepared in a conventional method according to the composition components and composition ratios shown in table 2.

[ TABLE 2 ]

Dosage form example 2: preparation of emulsionsAn emulsion comprising a chinese holly extract was prepared in a conventional method according to the composition components and composition ratios shown in table 3.

[ TABLE 3 ]

According to an aspect of the present invention, the extract of Chinese holly has an excellent effect of improving skin inflammation or skin irritation, and thus can be applied to various fields such as cosmetics, foods, pharmaceutical compositions, and the like.

While certain exemplary embodiments and implementations have been described herein, other embodiments and modifications will be apparent from this description. The inventive concept is therefore not limited to the embodiments but is to be accorded the widest scope consistent with the claims appended hereto, and various modifications and equivalent arrangements will be apparent to those skilled in the art.

<110> kesi meishi co

<120> a composition for preventing or treating inflammation comprising ilex cornuta extract and use thereof

<130>PX059089

<150>KR 10-2019-0023533

<151>2019-02-28

<160>12

<170>KoPatentIn 3.0

<210>1

<211>21

<212>DNA

<213> Artificial sequence

<220>

<223> TSLP Forward primer

<400>1

gctatctggt gcccaggcta t 21

<210>2

<211>21

<212>DNA

<213> Artificial sequence

<220>

<223> TSLP reverse primer

<400>2

cgacgccaca atccttgtaa t 21

<210>3

<211>18

<212>DNA

<213> Artificial sequence

<220>

<223> TARC Forward primer

<400>3

cttctctgca gcacatcc 18

<210>4

<211>19

<212>DNA

<213> Artificial sequence

<220>

<223> TARC reverse primer

<400>4

aagacctctc aaggctttg 19

<210>5

<211>20

<212>DNA

<213> Artificial sequence

<220>

<223> MDC forward primer

<400>5

gcatggctcg cctacagact 20

<210>6

<211>20

<212>DNA

<213> Artificial sequence

<220>

<223> MDC reverse primer

<400>6

gcagggaggg aggcagagga 20

<210>7

<211>20

<212>DNA

<213> Artificial sequence

<220>

<223> IL-6 Forward primer

<400>7

tacccccagg agaagattcc 20

<210>8

<211>20

<212>DNA

<213> Artificial sequence

<220>

<223> IL-6 reverse primer

<400>8

ttttctgcca gtgcctcttt 20

<210>9

<211>24

<212>DNA

<213> Artificial sequence

<220>

<223> IL-8 Forward primer

<400>9

ccaacacaga aattattgta aagc 24

<210>10

<211>21

<212>DNA

<213> Artificial sequence

<220>

<223> IL-8 reverse primer

<400>10

tgaattctca gccctcttca a 21

<210>11

<211>20

<212>DNA

<213> Artificial sequence

<220>

<223> beta actin forward primer

<400>11

ggccatctct tgctcgaagt 20

<210>12

<211>20

<212>DNA

<213> Artificial sequence

<220>

<223> beta actin reverse primer

<400>12

gacaccttca acaccccagc 20

Claims

1. A cosmetic composition for preventing or improving skin inflammation comprises Chinese holly extract as effective component.

2. The cosmetic composition of claim 1, wherein,

the prevention or improvement of the skin inflammation is prevention or improvement of at least one selected from the group consisting of atopic dermatitis, pruritus, redness, erythema, eczema, seborrheic dermatitis, psoriasis, and acne.

3. The cosmetic composition of claim 1, wherein,

the extract is folium Ilicis Cornutae extract.

4. The cosmetic composition of claim 1, wherein,

the extract is C1-C6 alcohol, water or mixture thereof.

5. The cosmetic composition of claim 1, wherein,

the extract is an ethanol extract.

6. A food composition for preventing or improving skin inflammation comprises Chinese holly extract as an effective ingredient.

7. A pharmaceutical composition for preventing or treating skin inflammation comprises Chinese holly extract as an effective ingredient.

8. A skin external composition for preventing or improving skin inflammation comprises Chinese holly extract as effective component.

9. A cosmetic composition for preventing or improving skin irritation comprises Chinese holly extract as an effective ingredient.

10. Use of a composition comprising a Chinese holly extract for the preparation of a cosmetic for preventing or improving skin inflammation.

11. Use of a composition comprising a Chinese holly extract for the preparation of a medicament for preventing or treating skin inflammation.